Serina Therapeutics (SER) announced that it has dosed the first patient in its Phase 1b registrational clinical trial evaluating SER-252 in patients with advanced Parkinson’s disease.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SER:
- Serina Therapeutics says first patient enrolled in Phase 1b trial of SER-252
- Serina Therapeutics files to sell 7.72M shares of common stock for holders
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- This Is Why Serina Therapeutics Stock (SER) Rocketed Today
- Serina Therapeutics announces FDA clearance of SER-252 new drug application